Update on the Phase 4 Confirmatory Study of ADUHELM®
Biogen Inc. (Nasdaq: BIIB) and Eisai Co., Ltd. (Tokyo, Japan)
today provided an important update on the continuing progress of
the Phase 4 post-marketing confirmatory study of ADUHELM®
(aducanumab-avwa) 100 mg/mL injection for intravenous use in
Alzheimer’s disease.
The companies anticipate submitting the final protocol for
review to the U.S. Food and Drug Administration (FDA) in March
2022, with the initiation of patient screening in May 2022. The
study is a post-marketing requirement of the FDA’s accelerated
approval and will be a global, placebo-controlled trial, aiming to
enroll more than 1,300 early Alzheimer’s disease patients, with a
primary clinical endpoint at 18 months after treatment initiation.
Based on enrollment rates from the previous Phase 3 trials with
ADUHELM, the primary completion date is expected to be
approximately four years after the study begins. The trial will
also include a long-term extension to collect longer-term treatment
data for up to 48 months.
“We are delivering on our commitment to accelerate the timelines
with the goal to complete the confirmatory study well ahead of
schedule,” said Priya Singhal M.D., M.P.H., Head of Global Safety
& Regulatory Sciences and interim Head of Research &
Development at Biogen. “Together with EMBARK, Biogen’s redosing
study, and the ICARE AD study, we aim to provide data from
real-world practice and clinical trials to further inform patient
and physician decisions about treatment.”
“I am very encouraged by this update and Biogen’s and Eisai’s
goal to complete the trial in four years after its initiation,
approximately half of the time that the FDA provided as part of the
accelerated approval,” said Marwan Sabbagh, M.D., FAAN, Professor
of Neurology, Alzheimer's and Memory Disorders Division, Barrow
Neurological Institute. “This is a significant commitment from the
companies. It takes time to execute a complex, global trial of this
nature, so I am pleased to see the high level of priority being
afforded to this study.”
The companies will continue to work with FDA, external
stakeholders and regulators in other geographies on the study
design.
About ADUHELM® (aducanumab-avwa)
injection 100 mg/mL solution for intravenous useIn the
United States, ADUHELM is indicated for the treatment of
Alzheimer’s disease. Treatment with ADUHELM should be initiated in
patients with mild cognitive impairment or mild dementia stage of
disease, the population in which treatment was initiated in
clinical trials. There are no safety or effectiveness data on
initiating treatment at earlier or later stages of the disease than
were studied. This indication is approved under accelerated
approval based on reduction in amyloid beta plaques observed in
patients treated with ADUHELM. Continued approval for this
indication may be contingent upon verification of clinical benefit
in confirmatory trial(s).
ADUHELM is a monoclonal antibody directed against amyloid beta.
The accumulation of amyloid beta plaques in the brain is a defining
pathophysiological feature of Alzheimer’s disease. The accelerated
approval of ADUHELM in the United States has been granted based on
data from clinical trials showing the effect of ADUHELM on reducing
amyloid beta plaques, a surrogate biomarker that is reasonably
likely to predict clinical benefit, in this case a reduction in
clinical decline.
ADUHELM can cause serious side effects including: Amyloid
Related Imaging Abnormalities or “ARIA”. ARIA is a common side
effect that does not usually cause any symptoms but can be serious.
Although most people do not have symptoms, some people may have
symptoms such as: headache, confusion, dizziness, vision changes
and nausea. The patient’s healthcare provider will do magnetic
resonance imaging (MRI) scans before and during treatment with
ADUHELM to check for ARIA. ADUHELM can also cause serious allergic
reactions. The most common side effects of ADUHELM include:
swelling in areas of the brain, with or without small spots of
bleeding in the brain or on the surface of the brain (ARIA);
headache; and fall. Patients should call their healthcare provider
for medical advice about side effects.
As of October 2017, Biogen and Eisai Co., Ltd. are collaborating
on the global co-development and co-promotion of aducanumab.
Please click here for U.S. full Prescribing Information,
including Medication Guide, for ADUHELM.
About BiogenAs pioneers in neuroscience, Biogen
discovers, develops, and delivers worldwide innovative therapies
for people living with serious neurological diseases as well as
related therapeutic adjacencies. One of the world’s first global
biotechnology companies, Biogen was founded in 1978 by Charles
Weissmann, Heinz Schaller, Sir Kenneth Murray, and Nobel Prize
winners Walter Gilbert and Phillip Sharp. Today, Biogen has the
leading portfolio of medicines to treat multiple sclerosis, has
introduced the first approved treatment for spinal muscular
atrophy, and is providing the first and only approved treatment to
address a defining pathology of Alzheimer’s disease. Biogen is also
commercializing biosimilars and focusing on advancing the
industry’s most diversified pipeline in neuroscience that will
transform the standard of care for patients in several areas of
high unmet need.
In 2020, Biogen launched a bold 20-year, $250 million initiative
to address the deeply interrelated issues of climate, health, and
equity. Healthy Climate, Healthy Lives™ aims to eliminate fossil
fuels across the company’s operations, build collaborations with
renowned institutions to advance the science to improve human
health outcomes, and support underserved communities.
The company routinely posts information that may be important to
investors on its website at www.biogen.com. To learn more,
please visit www.biogen.com and follow Biogen on social
media
– Twitter, LinkedIn, Facebook, YouTube.
About Eisai Co., Ltd.Eisai Co., Ltd. is a
leading global pharmaceutical company headquartered in Japan.
Eisai’s corporate philosophy is based on the human health care
(hhc) concept, which is to give first thought to patients and
their families, and to increase the benefits that health care
provides to them. With a global network of R&D facilities,
manufacturing sites and marketing subsidiaries, we strive to
realize our hhc philosophy by delivering innovative
products to target diseases with high unmet medical needs, with a
particular focus in our strategic areas of Neurology and
Oncology.
Leveraging the experience gained from the development and
marketing of a treatment for Alzheimer’s disease, Eisai aims to
establish the “Eisai Dementia Platform.” Through this platform,
Eisai plans to deliver novel benefits to those living with dementia
and their families through constructing a “Dementia Ecosystem,” by
collaborating with partners such as medical organizations,
diagnostic development companies, research organizations, and
bio-ventures in addition to private insurance agencies, finance
industries, fitness clubs, automobile makers, retailers, and care
facilities. For more information about Eisai Co., Ltd., please
visit https://www.eisai.com.
Biogen Safe HarborThis news release contains
forward-looking statements, including statements made pursuant to
the safe harbor provisions of the Private Securities Litigation
Reform Act of 1995, about potential regulatory discussions,
submissions and approvals and the timing thereof, the potential
clinical effects of ADUHELM; the potential benefits, safety and
efficacy of ADUHELM; Biogen’s strategy and plans; potential of, and
expectations for, Biogen’s commercial business and pipeline
programs, including ADUHELM and the post-marketing required study;
planning and timing for the commercial launch of, and access to,
ADUHELM; anticipated manufacturing, distribution, and supply of
ADUHELM; the treatment of Alzheimer’s disease; the anticipated
benefits and potential of Biogen’s collaboration arrangements with
Eisai; the potential of Biogen’s commercial business and pipeline
programs, including ADUHELM; and risks and uncertainties associated
with drug development and commercialization. These statements may
be identified by words such as “aim,” “anticipate,” “believe,”
“could,” “estimate,” “expect,” “forecast,” “intend,” “may,” “plan,”
“possible,” “potential,” “will,” “would” and other words and terms
of similar meaning. Drug development and commercialization involve
a high degree of risk, and only a small number of research and
development programs result in commercialization of a product.
Results in early stage clinical trials may not be indicative of
full results or results from later stage or larger scale clinical
trials and do not ensure regulatory approval. You should not place
undue reliance on these statements or the scientific data
presented.
These statements involve risks and uncertainties that could
cause actual results to differ materially from those reflected in
such statements, including, without limitation, uncertainty of
success in the development and commercialization of ADUHELM; risks
relating to the launch of ADUHELM, including preparedness of
healthcare providers to treat patients, the ability to obtain and
maintain adequate reimbursement for ADUHELM, and other unexpected
difficulties or hurdles; unexpected concerns that may arise from
additional data or analysis obtained during clinical trials; the
occurrence of adverse safety events, restrictions on use, or
product liability claims; regulatory authorities may require
additional information or further studies, or may fail or refuse to
approve or may delay approval of Biogen’s drug candidates,
including ADUHELM; risks of unexpected costs or delays; the risk of
other unexpected hurdles; risks relating to investment in our
manufacturing capacity; problems with our manufacturing processes;
failure to protect and enforce our data, intellectual property, and
other proprietary rights and uncertainties relating to intellectual
property claims and challenges; third party collaboration risks;
risks associated with current and potential future healthcare
reforms; risks relating to the distribution and sale by third
parties of counterfeit or unfit versions of our products; and the
direct and indirect impacts of the ongoing COVID-19 pandemic on our
business, results of operations and financial condition. The
foregoing sets forth many, but not all, of the factors that could
cause actual results to differ from Biogen’s expectations in any
forward-looking statement. Investors should consider this
cautionary statement as well as the risk factors identified in
Biogen’s most recent annual or quarterly report and in other
reports Biogen has filed with the U.S. Securities and Exchange
Commission. These statements are based on Biogen’s current beliefs
and expectations and speak only as of the date of this news
release. Biogen does not undertake any obligation to publicly
update any forward-looking statements, whether as a result of new
information, future developments or otherwise.
MEDIA CONTACTS:BiogenAshleigh Koss+ 1 908 205
2572public.affairs@biogen.comEisai Inc. (U.S.
Media) Public Relations Department TEL : 1 201
753 1945 Eisai Co., Ltd. (Media Outside the
U.S.) Public Relations Department TEL : +81 (0)3
3817 5120 |
|
INVESTOR CONTACTS:BiogenMike Hencke+1 781 464
2442IR@biogen.com Eisai Co.,
Ltd. Investor Relations Department TEL:
+81-(0)70-8688-9685] |
Biogen (TG:IDP)
Gráfico Histórico do Ativo
De Mar 2024 até Abr 2024
Biogen (TG:IDP)
Gráfico Histórico do Ativo
De Abr 2023 até Abr 2024